We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.03% | 28.83 | 6,763 | 09:52:56 |
From May 2019 to May 2024
By Tess Stynes
Pfizer Inc. (PFE) said two Phase 3 studies to evaluate the effectiveness and safety of its treatment for adults with moderate-to-severe plaque psoriasis showed positive results.
The studies of the twice-daily pill--known as tofacitinib-- at two dosing levels was more effective than a placebo in achieving a response of "clear" or "almost clear" at 16 weeks and in the portion of patients achieving at least a 75% reduction in the severity and area affected by psoriasis.
Pfizer plans to submit a supplemental new drug application to the U.S. Food and Drug Administration by early next year.
Tofacitinib--sold domestically under the brand name Xeljanz---is approved in more than 20 countries for adults with hard-to-treat cases of moderate-to-severe rheumatoid arthritis.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
